Doxorubicin and paclitaxel in advanced breast carcinoma: Importance of prior adjuvant anthracycline therapy

Cancer

Volumn 89, Issue 11, 2000, Pages 2169-2175

  Lluch, Ana ^a   Ojeda, Belén ^b   Colomer, Ramon ^c   Barnadas, Agustí ^d   Massuti, Bartomeu ^e   Casado, Antonio ^f   Angeles, Cristina ^a   Maroto, Pablo ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL SANT PAU   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Adriamycin; Advanced breast carcinoma; Cardiotoxicity; Chemother apy; Doxorubicin; Paclitaxel; Toxicity

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEVER; HEART FUNCTION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; STROKE VOLUME;

EID: 0034545129     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001201)89:11<2169::AID-CNCR4>3.0.CO;2-9     Document Type: Article

References (19)

1. Treatment of metastatic disease
2. Malignant tumors of the breast
3. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel
4. The influence of chremophor EL on the cell cycle effects of paclitaxel in human tumor cell lines
5. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells
6. Review of recent trials of chemotherapy for advanced breast cancer: The taxanes
7. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer
8. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
9. Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic
10. Theoretical and practical aspects of paclitaxel scheduling
11. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
12. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer
13. Reporting results of cancer treatment
14. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
15. Paclitaxel plus doxorubicin in metastatic breast cancer: Preliminary analysis of cardiotoxicity
16. Three-year follow-up in women with metastatic breast cancer after bolus doxorubicin and paclitaxel infused over 3 hours
17. The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer
18. Phase II of doxorubicin/taxol in metastatic breast cancer
19. Construction and validation of a practical prognostic index for patients with metastatic breast cancer